Drug Type Small molecule drug |
Synonyms XZP 3287, XZP-3287, XZP3287 |
Target |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC27H36N8O5 |
InChIKeyNHANOMFABJQAAH-UHFFFAOYSA-N |
CAS Registry1374639-75-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | NDA/BLA | CN | 30 Aug 2023 | |
Advanced breast cancer | Phase 3 | CN | 16 Nov 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 27 Apr 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 27 Apr 2018 | |
Prostatic Cancer | IND Approval | CN | 28 Jun 2023 |
NCT04539496 (ASCO2023) Manual | Phase 2 | Hormone receptor positive HER2 negative breast cancer HR Positive | HER2 Negative | 131 | ollitpjptl(zxazhsdyas) = uiffndhvsc tjhipduzuc (oooeqzqvmp, 16.0 - 31.1) View more | Positive | 31 May 2023 | |
(subgroups with visceral disease) | ollitpjptl(zxazhsdyas) = cmbwjjptkn tjhipduzuc (oooeqzqvmp, 13.6 - 29.5) View more | ||||||
Phase 1 | 16 | oqhvdcbono(cqqjmlezet) = hnewbkzmxo vkqafffsbs (brhbjrgivf ) View more | - | 29 Sep 2019 |